Evotec Acquires Bionamics to Accelerate 'EVT Innovate' Strategy
News Mar 29, 2014
Evotec AG has announced the acquisition of the Germany-based Bionamics GmbH. Bionamics is an asset management company that focuses on the translation of academic innovations into attractive assets for the biotech and Pharma industry.
The transaction comprises the acquisition of all shares of Bionamics against cash and future milestone payments. Next to an experienced management team Bionamics brings a portfolio of highly attractive and fully funded projects especially in neurodegeneration and CNS to Evotec.
Further financial details of the transaction remain undisclosed.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "With the acquisition of Bionamics we accelerate our EVT Innovate strategy and enlarge our reach towards outstanding innovations. We welcome the openness of Bionamics to join the discovery infrastructure of Evotec. We are also very happy to welcome Dr Timm Jessen back at Evotec. In his new management role, Dr Jessen will be responsible for the commercialization of "EVT Innovate" projects."
Dr Timm Jessen, Managing Director of Bionamics GmbH, commented: "We highly value Evotec's strategic appreciation of our work and its success as demonstrated e.g. in managing the NEU² programme, a consortium of academic, biotech and Pharma partners focussing on novel products to treat Multiple Sclerosis and other neurodegenerative diseases. The combination of our management skills with Evotec's strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us. I very much look forward to expand this concept further within the Evotec Group."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018